Primary Graft Dysfunction in Lung Transplantation: A Review of Mechanisms and Future Applications.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
24
7
2023
pubmed:
19
1
2023
entrez:
18
1
2023
Statut:
ppublish
Résumé
Lung allograft recipients have worse survival than all other solid organ transplant recipients, largely because of primary graft dysfunction (PGD), a major form of acute lung injury affecting a third of lung recipients within the first 72 h after transplant. PGD is the clinical manifestation of ischemia-reperfusion injury and represents the predominate cause of early morbidity and mortality. Despite PGD's impact on lung transplant outcomes, no targeted therapies are currently available; hence, care remains supportive and largely ineffective. This review focuses on molecular and innate immune mechanisms of ischemia-reperfusion injury leading to PGD. We also discuss novel research aimed at discovering biomarkers that could better predict PGD and potential targeted interventions that may improve outcomes in lung transplantation.
Identifiants
pubmed: 36650643
doi: 10.1097/TP.0000000000004503
pii: 00007890-202308000-00013
doi:
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1687-1697Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report funding from the JLH Foundation. G.L. consults for TransMedics, Inc. and Abiomed and receives grant support at Baylor College of Medicine from TransMedics, Inc., Abiomed, AtriCure, and Abbott. The authors report no other conflicts of interest.
Références
Valapour M, Lehr CJ, Skeans MA, et al. OPTN/SRTR 2016 annual data report: lung. Am J Transplant. 2018;18(Suppl 1):363–433.
Diamond JM, Lee JC, Kawut SM, et al.; Lung Transplant Outcomes Group. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med. 2013;187:527–534.
Whitson BA, Prekker ME, Herrington CS, et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant. 2007;26:1004–1011.
Warnecke G, Van Raemdonck D, Smith MA, et al. Normothermic ex-vivo preservation with the portable Organ Care System lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study. Lancet Respir Med. 2018;6:357–367.
Chiu S, Bharat A. Role of monocytes and macrophages in regulating immune response following lung transplantation. Curr Opin Organ Transplant. 2016;21:239–245.
Laubach VE, Sharma AK. Mechanisms of lung ischemia-reperfusion injury. Curr Opin Organ Transplant. 2016;21:246–252.
Snell GI, Yusen RD, Weill D, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: definition and grading-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2017;36:1097–1103.
Bharat A, Kuo E, Steward N, et al. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg. 2008;86:189–195; discussion 196–187.
Bharat A, Narayanan K, Street T, et al. Early posttransplant inflammation promotes the development of alloimmunity and chronic human lung allograft rejection. Transplantation. 2007;83:150–158.
Gielis JF, Boulet GA, Briedé JJ, et al. Longitudinal quantification of radical bursts during pulmonary ischaemia and reperfusion. Eur J Cardiothorac Surg. 2015;48:622–629.
Cui Y, Wang Y, Li G, et al. The Nox1/Nox4 inhibitor attenuates acute lung injury induced by ischemia-reperfusion in mice. PLoS One. 2018;13:e0209444.
Sharma AK, Mulloy DP, Le LT, et al. NADPH oxidase mediates synergistic effects of IL-17 and TNF-alpha on CXCL1 expression by epithelial cells after lung ischemia-reperfusion. Am J Physiol Lung Cell Mol Physiol. 2014;306:L69–L79.
Fernandez LG, Sharma AK, LaPar DJ, et al. Adenosine A1 receptor activation attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2013;145:1654–1659.
Lau CL, Zhao Y, Kim J, et al. Enhanced fibrinolysis protects against lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2009;137:1241–1248.
Lan CC, Peng CK, Tang SE, et al. Inhibition of Na-K-Cl cotransporter isoform 1 reduces lung injury induced by ischemia-reperfusion. J Thorac Cardiovasc Surg. 2017;153:206–215.
Sharma AK, Charles EJ, Zhao Y, et al. Pannexin-1 channels on endothelial cells mediate vascular inflammation during lung ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol. 2018;315:L301–L312.
Haywood N, Ta HQ, Zhang A, et al. Endothelial transient receptor potential vanilloid 4 channels mediate lung ischemia-reperfusion injury. Ann Thorac Surg. 2022;113:1256–1264.
Li W, Terada Y, Tyurina YY, et al. Necroptosis triggers spatially restricted neutrophil-mediated vascular damage during lung ischemia reperfusion injury. Proc Natl Acad Sci USA. 2022;119:e2111537119.
Chatterjee S, Nieman GF, Christie JD, et al. Shear stress-related mechanosignaling with lung ischemia: lessons from basic research can inform lung transplantation. Am J Physiol Lung Cell Mol Physiol. 2014;307:L668–L680.
Shah RJ, Emtiazjoo AM, Diamond JM, et al. Plasma complement levels are associated with primary graft dysfunction and mortality after lung transplantation. Am J Respir Crit Care Med. 2014;189:1564–1567.
Westall GP, Snell GI, McLean C, et al. C3d and C4d deposition early after lung transplantation. J Heart Lung Transplant. 2008;27:722–728.
Kulkarni HS, Ramphal K, Ma L, et al. Local complement activation is associated with primary graft dysfunction after lung transplantation. JCI Insight. 2020;5:e138358.
Schmid RA, Zollinger A, Singer T, et al. Effect of soluble complement receptor type 1 on reperfusion edema and neutrophil migration after lung allotransplantation in swine. J Thorac Cardiovasc Surg. 1998;116:90–97.
Scherer M, Demertzis S, Langer F, et al. C1-esterase inhibitor reduces reperfusion injury after lung transplantation. Ann Thorac Surg. 2002;73:233–238; discussion 238-9.
Kreisel D, Sugimoto S, Tietjens J, et al. Bcl3 prevents acute inflammatory lung injury in mice by restraining emergency granulopoiesis. J Clin Invest. 2011;121:265–276.
Götzfried J, Smirnova NF, Morrone C, et al. Preservation with alpha1-antitrypsin improves primary graft function of murine lung transplants. J Heart Lung Transplant. 2018;37:1021–1028.
Zhao Y, Sharma AK, LaPar DJ, et al. Depletion of tissue plasminogen activator attenuates lung ischemia-reperfusion injury via inhibition of neutrophil extravasation. Am J Physiol Lung Cell Mol Physiol. 2011;300:L718–L729.
Zheng Z, Chiu S, Akbarpour M, et al. Donor pulmonary intravascular nonclassical monocytes recruit recipient neutrophils and mediate primary lung allograft dysfunction. Sci Transl Med. 2017;9:eaal4508.
Fiser SM, Tribble CG, Long SM, et al. Lung transplant reperfusion injury involves pulmonary macrophages and circulating leukocytes in a biphasic response. J Thorac Cardiovasc Surg. 2001;121:1069–1075.
Liu X, Cao H, Li J, et al. Autophagy induced by DAMPs facilitates the inflammation response in lungs undergoing ischemia-reperfusion injury through promoting TRAF6 ubiquitination. Cell Death Differ. 2017;24:683–693.
Calabrese DR, Aminian E, Mallavia B, et al. Natural killer cells activated through NKG2D mediate lung ischemia-reperfusion injury. J Clin Invest. 2021;131:e137047.
Hsu J, Krishnan A, Lee SA, et al. CD3 + CD4 - CD8 - double-negative αβ T cells attenuate lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2021;161:e81–e90.
Kurihara C, Lecuona E, Wu Q, et al. Crosstalk between nonclassical monocytes and alveolar macrophages mediates transplant ischemia-reperfusion injury through classical monocyte recruitment. JCI Insight. 2021;6:e147282.
Hsiao HM, Fernandez R, Tanaka S, et al. Spleen-derived classical monocytes mediate lung ischemia-reperfusion injury through IL-1beta. J Clin Invest. 2018;128:2833–2847.
Spahn JH, Li W, Bribriesco AC, et al. DAP12 expression in lung macrophages mediates ischemia/reperfusion injury by promoting neutrophil extravasation. J Immunol. 2015;194:4039–4048.
Sharma AK, LaPar DJ, Zhao Y, et al. Natural killer T cell-derived IL-17 mediates lung ischemia-reperfusion injury. Am J Respir Crit Care Med. 2011;183:1539–1549.
Chen-Yoshikawa TF. Ischemia-reperfusion injury in lung transplantation. Cells. 2021;10:1333.
Panday A, Sahoo MK, Osorio D, et al. NADPH oxidases: an overview from structure to innate immunity-associated pathologies. Cell Mol Immunol. 2015;12:5–23.
Reece TB, Ellman PI, Maxey TS, et al. Adenosine A2A receptor activation reduces inflammation and preserves pulmonary function in an in vivo model of lung transplantation. J Thorac Cardiovasc Surg. 2005;129:1137–1143.
Mulloy DP, Sharma AK, Fernandez LG, et al. Adenosine A3 receptor activation attenuates lung ischemia-reperfusion injury. Ann Thorac Surg. 2013;95:1762–1767.
Wagner CE, Pope NH, Charles EJ, et al. Ex vivo lung perfusion with adenosine A 2 A receptor agonist allows prolonged cold preservation of lungs donated after cardiac death. J Thorac Cardiovasc Surg. 2016;151:538–545.
Gazoni LM, Walters DM, Unger EB, et al. Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg. 2010;140:440–446.
Livingstone SA, Wildi KS, Dalton HJ, et al. Coagulation dysfunction in acute respiratory distress syndrome and its potential impact in inflammatory subphenotypes. Front Med (Lausanne). 2021;8:723217.
Ware LB, Camerer E, Welty-Wolf K, et al. Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2006;291:L307–L311.
Pinsky DJ, Liao H, Lawson CA, et al. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest. 1998;102:919–928.
Rosenbaum T, Benítez-Angeles M, Sánchez-Hernández R, et al. TRPV4: a physio and pathophysiologically significant ion channel. Int J Mol Sci. 2020;21:3837.
Wu MY, Yiang GT, Liao WT, et al. Current mechanistic concepts in ischemia and reperfusion injury. Cell Physiol Biochem. 2018;46:1650–1667.
Patel PM, Connolly MR, Coe TM, et al. Minimizing ischemia reperfusion injury in xenotransplantation. Front Immunol. 2021;12:681504.
Chatterjee S. Endothelial mechanotransduction, redox signaling and the regulation of vascular inflammatory pathways. Front Physiol. 2018;9:524.
Ali HA, Pavlisko EN, Snyder LD, et al. Complement system in lung transplantation. Clin Transplant. 2018;32:e13208.
Schueler S, De Valeria PA, Hatanaka M, et al. Successful twenty-four-hour lung preservation with donor core cooling and leukocyte depletion in an orthotopic double lung transplantation model. J Thorac Cardiovasc Surg. 1992;104:73–82.
Eppinger MJ, Jones ML, Deeb GM, et al. Pattern of injury and the role of neutrophils in reperfusion injury of rat lung. J Surg Res. 1995;58:713–718.
Uthoff K, Zehr KJ, Lee PC, et al. Neutrophil modulation results in improved pulmonary function after 12 and 24 hours of preservation. Ann Thorac Surg. 1995;59:7–12.
Eppinger MJ, Deeb GM, Bolling SF, et al. Mediators of ischemia-reperfusion injury of rat lung. Am J Pathol. 1997;150:1773–1784.
Zhao M, Fernandez LG, Doctor A, et al. Alveolar macrophage activation is a key initiation signal for acute lung ischemia-reperfusion injury. Am J Physiol Lung Cell Mol Physiol. 2006;291:L1018–L1026.
Gilmont RR, Dardano A, Engle JS, et al. TNF-alpha potentiates oxidant and reperfusion-induced endothelial cell injury. J Surg Res. 1996;61:175–182.
Laan M, Cui ZH, Hoshino H, et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol. 1999;162:2347–2352.
Sharma AK, LaPar DJ, Stone ML, et al. Receptor for advanced glycation end products (RAGE) on iNKT cells mediates lung ischemia-reperfusion injury. Am J Transplant. 2013;13:2255–2267.
Altemeier WA, Liles WC, Villagra-Garcia A, et al. Ischemia-reperfusion lung injury is attenuated in MyD88-deficient mice. PLoS One. 2013;8:e77123.
Diamond JM, Arcasoy S, Kennedy CC, et al. Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, part II: epidemiology, risk factors, and outcomes—a 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2017;36:1104–1113.
Mathur A, Baz M, Staples ED, et al. Cytokine profile after lung transplantation: correlation with allograft injury. Ann Thorac Surg. 2006;81:1844–1849; discussion 1849–1850.
Hoffman SA, Wang L, Shah CV, et al.; Lung Transplant Outcomes Group. Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation. Am J Transplant. 2009;9:389–396.
Shah RJ, Diamond JM, Lederer DJ, et al. Plasma monocyte chemotactic protein-1 levels at 24 hours are a biomarker of primary graft dysfunction after lung transplantation. Transl Res. 2012;160:435–442.
Christie JD, Robinson N, Ware LB, et al. Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction. Am J Respir Crit Care Med. 2007;175:69–74.
Christie JD, Shah CV, Kawut SM, et al.; Lung Transplant Outcomes Group. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med. 2009;180:1010–1015.
Chacon-Alberty L, Kanchi RS, Ye S, et al. Plasma protein biomarkers for primary graft dysfunction after lung transplantation: a single-center cohort analysis. Sci Rep. 2022;12:16137.
Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011;364:1431–1440.
Kanou T, Nakahira K, Choi AM, et al. Cell-free DNA in human ex vivo lung perfusate as a potential biomarker to predict the risk of primary graft dysfunction in lung transplantation. J Thorac Cardiovasc Surg. 2021;162:490–499.e2.
Hashimoto K, Cypel M, Juvet S, et al. Higher M30 and high mobility group box 1 protein levels in ex vivo lung perfusate are associated with primary graft dysfunction after human lung transplantation. J Heart Lung Transplant. 2018;37:240–249.
Hashimoto K, Cypel M, Kim H, et al. Soluble adhesion molecules during ex vivo lung perfusion are associated with posttransplant primary graft dysfunction. Am J Transplant. 2017;17:1396–1404.
Hsin MK, Zamel R, Cypel M, et al. Metabolic profile of ex vivo lung perfusate yields biomarkers for lung transplant outcomes. Ann Surg. 2018;267:196–197.
Diamond JM, Akimova T, Kazi A, et al.; Lung Transplant Outcomes Group. Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction. Am J Respir Crit Care Med. 2014;189:567–575.
Diamond JM, Meyer NJ, Feng R, et al.; Lung Transplant Outcomes Group. Variation in PTX3 is associated with primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med. 2012;186:546–552.
Prasad NK, Pasrija C, Talaie T, et al. Ex vivo lung perfusion: current achievements and future directions. Transplantation. 2021;105:979–985.
Diamond JM, Porteous MK, Roberts LJ 2nd, et al.; Lung Transplant Outcomes Group. The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia. J Heart Lung Transplant. 2016;35:500–507.
Shaver CM, Wickersham N, McNeil JB, et al.; Lung Transplant Outcomes Group (LTOG). Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury. JCI Insight. 2018;3:e98546.
Ghaidan H, Stenlo M, Niroomand A, et al. Reduction of primary graft dysfunction using cytokine adsorption during organ preservation and after lung transplantation. Nat Commun. 2022;13:4173.
Lin H, Chen M, Tian F, et al. Alpha1-anti-trypsin improves function of porcine donor lungs during ex-vivo lung perfusion. J Heart Lung Transplant. 2018;37:656–666.
Motoyama H, Chen F, Hijiya K, et al. Plasmin administration during ex vivo lung perfusion ameliorates lung ischemia-reperfusion injury. J Heart Lung Transplant. 2014;33:1093–1099.
Keshavjee S, Davis RD, Zamora MR, et al. A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg. 2005;129:423–428.
Sommer W, Tudorache I, Kühn C, et al. C1-esterase-inhibitor for primary graft dysfunction in lung transplantation. Transplantation. 2014;97:1185–1191.
Emaminia A, Lapar DJ, Zhao Y, et al. Adenosine A 2 A agonist improves lung function during ex vivo lung perfusion. Ann Thorac Surg. 2011;92:1840–1846.
Noda K, Shigemura N, Tanaka Y, et al. Hydrogen preconditioning during ex vivo lung perfusion improves the quality of lung grafts in rats. Transplantation. 2014;98:499–506.
Inci I, Hillinger S, Arni S, et al. Surfactant improves graft function after gastric acid-induced lung damage in lung transplantation. Ann Thorac Surg. 2013;95:1013–1019.
Inci I, Ampollini L, Arni S, et al. Ex vivo reconditioning of marginal donor lungs injured by acid aspiration. J Heart Lung Transplant. 2008;27:1229–1236.
Slama A, Schillab L, Barta M, et al. Standard donor lung procurement with normothermic ex vivo lung perfusion: a prospective randomized clinical trial. J Heart Lung Transplant. 2017;36:744–753.
Toronto Lung Transplant Group. Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med. 1986;314:1140–1145.